These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date, and reported results 2004-001155-11 A Randomized, Open Label, Phase II Study of OSI-7904L versus 5-FU/LV as First-Line Treatment in Patients with Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract bad-data
Reported results 2004-004106-25 A Phase II randomised, dose-ranging, double-masked, multi-center trial, in parallel groups, to determine the safety, efficacy and pharmacokinetics of intravitreous injections of pegaptanib sodium comp... 2006-09-05 due-trials
Listed as ongoing, but also has a completion date 2004-004296-11 An open label, non-comparative protocol for the use of pegaptanib sodium injection every 6 weeks in patients with exudative age-related macular degeneration (AMD). 2008-03-31 bad-data
Reported results 2004-004867-31 A Phase 3B/4, randomized, active controlled, double-masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of Macugen®... 2008-03-31 due-trials
Reported results 2005-001460-32 A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3, 0.03 or 0.00... 2011-07-15 due-trials
Reported results 2005-001747-29 A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients... 2014-06-25 due-trials
Reported results 2005-004337-18 A randomised, double-blind, placebo-controlled, multiple dose, time-lagged cohort, dose-escalation trial, investigating the pharmacodynamics, safety and tolerability, and the pharmacokinetics of PSN35... 2006-09-12 due-trials
Not reported 2006-000722-31 An Exploratory randomized, double-masked, multi-center, multi-dose comparative trial, in parallel groups, to explore the safety and efficacy of three different doses of intravitreous injections of peg... 2006-11-28 due-trials
Reported results 2006-005905-79 A Phase 2 Randomized Study of Tarceva® (erlotinib) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Newly Diagnosed Advanced Non-Small Cell Lung Cancer who have Tumors ... 2010-03-08 due-trials
Reported results 2009-012820-97 A Randomized, Double-Blind Placebo-Controlled Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma 2012-10-08 due-trials
Reported results 2009-016836-11 A Randomized, Phase 2 Study of Single-agent Erlotinib versus Oral Etoposide in Patients with Recurrent or Refractory Pediatric Ependymoma 2012-12-20 due-trials
Reported results 2010-018739-17 A Randomized, Placebo-controlled, Double-blind Phase 2 Study of Second-line Treatment with OSI-906 in Patients with Advanced Hepatocellular Carcinoma (HCC) after Failure of First-line Treatment with S... 2011-11-29 due-trials
Reported results 2010-023478-38 Open-label, Phase 2 Study of Single-agent Erlotinib for Patients with Pediatric Ependymoma Previously Treated with Oral Etoposide in Protocol OSI-774-205 2012-12-20 due-trials